Results 111 to 120 of about 4,309,747 (310)

Anti-Consumption Agents: Tirzepatide and Semaglutide for Treating Obesity-Related Diseases and Addictions, and Improving Life Expectancy

open access: yesProgress in cardiovascular diseases
American culture encourages overconsumption, fueled by ubiquitous availability and pervasive marketing of ultra-processed foods and other addictive substances. This chronic overindulgence has contributed to rising rates of obesity, type 2 diabetes (T2D),
James H. O'Keefe   +2 more
semanticscholar   +1 more source

VLCC to market CMFRI’s anti-obesity product The New Indian Express dated 29th May 2017 [PDF]

open access: yes, 2017
The Central Marine Fisheries Research Institute (CMFRI) has given VLCC the exclusive licence to use its recently-developed anti-obesity nutraceutical product CadalminTM Antihypercholesterolemic extract (CadalminTM ACe) for commercial production and ...
CMFRI, Library
core   +1 more source

Profile of High Obesity Areas in: Georgia [PDF]

open access: yes
Obesity is a major health problem on a national level, butit is particularly persistent in certain areas. The Centers forDisease Control and Prevention\u2019s (CDC) Programs to ReduceObesity in High Obesity Areas to Boost Prevention cooperativeagreement ...

core  

Long‐Term Risk of Rheumatoid Arthritis in Individuals With Autism Spectrum Disorder: A Population‐Based Matched Cohort Study

open access: yesAutism Research, EarlyView.
ABSTRACT To investigate the long‐term risk of rheumatoid arthritis (RA) among individuals with autism spectrum disorder (ASD), addressing potential immune comorbidity in ASD populations. A population‐based matched cohort was assembled using Swedish registers, including 46,164 individuals diagnosed with ASD between 1987 and 2017, matched to 4,634,895 ...
Evora Hailin Zhu   +10 more
wiley   +1 more source

Use of partial meal replacement in class 3 obesity in an Australian public weight management program

open access: yes, 2020
Background: Partial meal replacement (PMR) (one or two per day) is an effective tool for short-term weight loss. Evidence and acceptability for longer term use in people with class 3 obesity (BMI>40kg/m ) are lacking.
Kormas, Nick   +4 more
core  

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis   +5 more
wiley   +1 more source

Profile of High Obesity Areas in: Indiana [PDF]

open access: yes
Obesity is a major health problem on a national level, butcertain areas in the United States experience a much higherburden of the disease. The Centers for Disease Control andPrevention\u2019s (CDC) Division of Nutrition, Physical Activity, andObesity ...

core  

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić   +7 more
wiley   +1 more source

Nutrient molecules affecting the white-to-beige adipose tissue transition

open access: yesОжирение и метаболизм
Obesity is one of the most important health problems. Body weight can be controlled through a combination of a healthy diet and physical activity, but hypertrophic obesity is often complicated by other comorbidities such as type 2 diabetes mellitus (T2DM)
V. S. Egorova   +2 more
doaj   +1 more source

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy